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Sjoegren’s syndrome (SS) is a chronic autoimmune disease characterized by sicca syndrome and 
systemic manifestations [1]. IFNγ-inducible protein-16 (IFI16) is a viral DNA sensor involved in 
infections and autoimmune diseases. In SS patients, IFI16 and anti-IFI16 antibodies can be detected 
in serum and salivary glands [2]. However, to date none of these findings were correlated with SS 
severity and disease activity. 
IFI16 and anti-IFI16 in serum, minor salivary glands and saliva were evaluated together with 
clinical characteristics and EULAR SS disease activity index (ESSDAI) of SS patients. 
Serum and tissue samples were analyzed as previously described [2], salivary anti-IFI16 IgG/IgA 
detection via ELISA based on horseradish peroxidase–conjugated rabbit anti-human IgG/IgA. 
Table 1 describes patient characteristics. Patient (a), with moderate systemic SS (Figure 1a), 
showed increased IFI16 expression in inflammatory and epithelial cells not only in nuclei, but also in 
the cytosol, very high serum IFI16 (472 ng/mL), and serum anti-IFI16 IgG (116 U/mL). Patient (b), 
with localized SS (Figure 1b), showed moderately increased nuclear expression of IFI16 both in 
inflammatory and epithelial cells and no serum IFI16/anti-IFI16 IgG. In patient (c), with mild systemic 
SS (Figure 1c), we observed poor inflammatory infiltrate, although salivary anti-IFI16 IgA (10 U/mL) 
and serum anti-IFI16 IgG (147 U/mL) were found. 
In saliva, IFI16 was not detected by Western blot. Recombinant IFI16 incubated at 37 °C was 
markedly degraded after 1h and completely degraded after 6 h in controls; completely degraded after 
1h in patient (a), and more slowly degraded in patients (b) and (c). 
Our results suggest that the expression and localization of IFI16 and anti-IFI16 may vary based 
on disease severity and activity of SS. Further experiments in a larger cohort of patients will allow us 
to better define the diagnostic and prognostic value of these biomarkers. 
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Table 1. Characteristics of patients. 
Parameter Patient (a) Patient (b) Patient (c) 
ESSDAI 12 0 3 
RF + - - 
Anti-SSA/Ro +++ ++ + 
Anti-IFI16 IgG U/mL Serum 116 (+) 102 (-) 147 (+) 
IFI16 ng/mL Serum 472 (++) 0.00 (-) 0.00 (-) 
Anti-IFI16 IgA U/mL Saliva 4.7 (-) 5.4 (-) 10 (+) 
Hypocomplementemia + - + 
Hypergammaglobulinemia + - + 
EULAR Sjoegren Syndrome Disease Activity Index, IFI16 IFNγ-inducible protein 16, RF rheumatoid 
factor, – negative, + positive, ++ high titre positivity, +++ very high titre positivity. 
Figure 1. Immunohistochemistry for IFI16 expression in minor salivary glands in three patients. IFI16 
staining is shown in brown and hematoxylin staining to highlight nuclei is in blue. (a) moderate 
systemic disease, (b) localized disease, (c) mild systemic disease. 
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